RE: AACR Poster25 Oct 2025 23:09
Integration with Targeted Therapies: Chemotherapy is often combined with targeted therapies (e.g., anti-EGFR drugs) or immunotherapies, increasing the number of agents.
Common Multi-Drug Regimens for Solid TumorsHere are examples of chemotherapy regimens for solid tumors that often include three or more drugs, or combine chemotherapy with other therapies:Breast Cancer:AC-T: Adriamycin (doxorubicin), Cyclophosphamide, followed by Taxol (paclitaxel)—a three-drug sequence.
CMF: Cyclophosphamide, Methotrexate, Fluorouracil (5-FU)—three drugs used in early-stage breast cancer.
May be combined with targeted therapies like trastuzumab (Herceptin) for HER2-positive tumors, effectively increasing the drug count.
Colorectal Cancer:FOLFOX: Folinic acid (leucovorin), Fluorouracil (5-FU), Oxaliplatin—three drugs, commonly used for stage III/IV colorectal cancer.
FOLFIRI: Folinic acid, Fluorouracil, Irinotecan—another three-drug regimen, often alternated with FOLFOX.
Frequently paired with anti-EGFR antibodies (e.g., cetuximab) or anti-VEGF drugs (e.g., bevacizumab), adding to the regimen.
Lung Cancer (Non-Small Cell Lung Cancer, NSCLC):Carboplatin + Paclitaxel + Pembrolizumab: A common triplet combining two chemotherapy drugs with an immunotherapy (PD-1 inhibitor) for advanced NSCLC.
Cisplatin + Pemetrexed: A doublet often supplemented with targeted therapies or maintenance drugs like pemetrexed, effectively increasing the agents used over time.
Pancreatic Cancer:FOLFIRINOX: Folinic acid, Fluorouracil, Irinotecan, Oxaliplatin—a four-drug regimen for metastatic pancreatic cancer in patients with good performance status.
Ovarian Cancer:Carboplatin + Paclitaxel: A standard doublet, often followed by maintenance therapy with PARP inhibitors (e.g., olaparib), increasing the overall drug count.
Head and Neck Cancer:TPF: Docetaxel, Cisplatin, Fluorouracil—three drugs used for induction chemotherapy in advanced cases, sometimes combined with anti-EGFR therapy like cetuximab.
Variations and ConsiderationsDoublets vs. Triplets:
While two-drug regimens (doublets) are common, especially for older patients or those with comorbidities, three or more drugs (triplets or sequential regimens) are standard for aggressive solid tumors (e.g., metastatic breast, colorectal, or pancreatic cancer) to maximize tumor response.
Additional Therapies: The integration of immunotherapy (e.g., checkpoint inhibitors) or targeted therapies (e.g., EGFR inhibitors, VEGF inhibitors) with chemotherapy often results in more than two drugs, especially in modern protocols for solid tumors.
Supportive Care: Drugs for side effect management (e.g., antiemetics, growth factors) are commonly given but aren’t counted as chemotherapy.
Clinical Trials:
In trials, the number of drugs varies. Early-phase trials may use a single agent, while later phases or real-world treatments combine multiple drugs for better outcomes. continued
Sign In
Follow the stocks
